Seed+ · Biotech
Signadori Bio: Seed+
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
Funding history
Seed+ · This round€11.1M
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage